Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory denosumab immunologic study in postmenopausal HER2‑negative breast cancer
2016-005210-22Phase 2Terminated
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in breast cancer, sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Change in intratumoral T-cell and myeloid cell numbers and function. Started Dec 2017; status: terminated.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-005210-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005210-22.